Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9167113 | 0.85 | NPSR1 (0.41) | NPSR1KEAP1HPGDCYP2C19POLB | |
| SCHEMBL9168227 | 0.85 | NPSR1 (0.41) | NPSR1KEAP1HPGDCYP2C19POLB | |
| SCHEMBL22684293 | 0.83 | FFAR1 (0.42) | NPSR1KEAP1HPGDCYP2C19POLB | |
| SCHEMBL1000052 | 0.82 | PTGER1 (0.47) | NPSR1KEAP1HPGDCYP2C19FFAR1 | |
| SCHEMBL999753 | 0.79 | AKR1B1 (0.43) | HPGDCYP2C19CA2 | |
| SCHEMBL6492831 | 0.76 | PARP1 (0.50) | KEAP1HPGDCYP2C19FFAR1HDAC3 | |
| SCHEMBL1000871 | 0.74 | HPGD (0.55) | NPSR1KEAP1HPGDCYP2C19POLB | |
| SCHEMBL115272 | 0.74 | HPGD (0.55) | NPSR1KEAP1HPGDCYP2C19POLB | |
| SCHEMBL89295 | 0.73 | KEAP1 (0.54) | NPSR1KEAP1HPGDCYP2C19FFAR1 | |
| SCHEMBL11413993 | 0.73 | FFAR1 (0.50) | NPSR1KEAP1HPGDCYP2C19FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903431-A | Carbon nano tube composite material and preparation method and application thereof | 浙江王点科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117903431-A | Carbon nano tube composite material and preparation method and application thereof | 浙江王点科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | NPSR1 1083/4885KEAP1 2576/4885HPGD 3355/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | NPSR1 1390/4885KEAP1 2843/4885HPGD 2090/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | NPSR1 4506/4885KEAP1 3833/4885HPGD 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.